Trust Company of Vermont’s Sarepta Therapeutics SRPT Stock Holding History

Trust Company of Vermont’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-2	Closed	-$250	–	1111
2024 Q3	$250	Buy	+2	New	+$276	﹤0.01%	1014
2021 Q2	–	Sell	-138	Closed	-$10K	–	797
2021 Q1	$10K	Buy	138 +13	+10%	+$1.2K	﹤0.01%	635
2020 Q4	$21K	Hold	125	–	–	﹤0.01%	540
2020 Q3	$18K	Hold	125	–	–	﹤0.01%	539
2020 Q2	$20K	Sell	125 -45	-26%	-$6.12K	﹤0.01%	538
2020 Q1	$17K	Hold	170	–	–	﹤0.01%	586
2019 Q4	$22K	Hold	170	–	–	﹤0.01%	597
2019 Q3	$13K	Sell	170 -8	-4%	-$945	﹤0.01%	706
2019 Q2	$27K	Buy	178 +170	+2,125%	+$20.7K	﹤0.01%	578
2019 Q1	$1K	Buy	+8	New	+$1.03K	﹤0.01%	955

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Trust Company of Vermont's SRPT Position: Q4 2024 in Review

Trust Company of Vermont sold out of Sarepta Therapeutics (SRPT) in Q4 2024, closing a stake of 2 shares — an estimated $250 sold.

Trust Company of Vermont first reported a position in SRPT in Q1 2019 and held it in 10 quarters. The position peaked at $27K in Q2 2019. 465 funds tracked by Wall St. Rank hold SRPT as of Q4 2024.

Trust Company of Vermont reported no remaining Sarepta Therapeutics position as of Q4 2024 after selling out during the quarter.
Trust Company of Vermont sold 2 Sarepta Therapeutics shares in Q4 2024, an estimated $250.
Trust Company of Vermont first reported a position in Sarepta Therapeutics in Q1 2019 and held it in 10 quarters.
Trust Company of Vermont's Sarepta Therapeutics position peaked at $27K in Q2 2019.
465 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2024.

Based on Trust Company of Vermont's 13F filing for Q4 2024, filed 15 Jan 2025.